NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Today, EMED Technologies, a global leader in drug delivery and infusion therapy innovation, today announced the issuance of U.S. Patent No. 12,403,243 that ...
image: Octapharma USA presented research at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting evaluating the efficacy and safety of cutaquig® (Immune Globulin Subcutaneous ...
Medical Device Network on MSN
KORU Medical receives FDA clearance for FreedomEDGE infusion system
Rystiggo is administered weekly, 3ml to 6ml over 15 to 30 minutes for six weeks.
SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果